Publications by authors named "Bernard Hemmer"

Multiple sclerosis (MS) is an inflammatory and neurodegenerative demyelinating disease of the central nervous system (CNS), most likely autoimmune in origin, usually beginning in early adulthood. The aetiology of the disease is not well understood; it is viewed currently as a multifactorial disease which results from complex interactions between genetic predisposition and environmental factors, of which a few are potentially modifiable. Improving our understanding of these factors can lead to new and more effective approaches to patient counselling and, possibly, prevention and management of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the occurrence of anti-drug antibodies (ADA) in patients with multiple sclerosis treated with biopharmaceuticals, revealing that several demographic and clinical factors influence ADA development.
  • Data was collected from multiple cohorts in Sweden, Denmark, Austria, and Germany, focusing on patients treated with interferon-beta (IFNβ) and natalizumab, allowing for a thorough analysis of factors affecting ADA risk.
  • Results indicated that older age, male sex, and specific types of IFNβ therapy increase the risk of ADA, with notable seasonal trends in Sweden and Germany warranting further research to understand the underlying causes.
View Article and Find Full Text PDF

Using retrospectively collected outcome data for treatment naïve subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN β) (n=424), we replicated the lack of a significant difference in efficacy between these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects.

View Article and Find Full Text PDF